Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PROT
CUSIPN/A
Phone+1-973-5446116
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity3,244.33%
Return on Assets90.15%
Miscellaneous
EmployeesN/A
Outstanding Shares7,910,000
Market Cap$79,110.00
Stromacel (OTCMKTS:PROT) Frequently Asked Questions
What is Stromacel's stock symbol?
Stromacel trades on the OTCMKTS under the ticker symbol "PROT."
Who are some of Stromacel's key competitors?
Some companies that are related to Stromacel include Arno Therapeutics (ARNI), Diagnocure (DGCRF), Medican Enterprises (MDCN), Altimmune (ALT), Can-Fite Biopharma (CANF), Circassia Pharmaceuticals (CIR), Cronos Group (CRON), Devonian Health Group (GSD), Exicure (XCUR), Galena Biopharma (SLS), Immunoprecise Antibodies (IPATF), IMV (IMV), Naturally Splendid Enterprises (NSP), Novacyt (NCYT) and Novoheart (NVH).
Who are Stromacel's key executives?
Stromacel's management team includes the folowing people:
- Mr. Michael Cohen, Founder, Chairman, CEO, Pres & COO (Age 51)
- Mr. Steven Byle J.D., Chief Technology Officer and Director (Age 50)
- Mr. Jason B. Isaacs, Sec. (Age 46)
- Ms. Jaci Mandil, Chief Exec. Officer of Proteoderm
Has Stromacel been receiving favorable news coverage?
News coverage about PROT stock has been trending somewhat positive on Friday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stromacel earned a daily sentiment score of 0.07 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Stromacel.
How do I buy shares of Stromacel?
Shares of PROT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stromacel's stock price today?
One share of PROT stock can currently be purchased for approximately $0.05.
How big of a company is Stromacel?
Stromacel has a market capitalization of $79,110.00.
How can I contact Stromacel?
Stromacel's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116.
MarketBeat Community Rating for Stromacel (OTCMKTS PROT)
MarketBeat's community ratings are surveys of what our community members think about Stromacel and other stocks. Vote "Outperform" if you believe PROT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROT will underperform the S&P 500 over the long term. You may vote once every thirty days.
